A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.
Also called NCT03098979
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 305 participants
- Sponsor
- Registry
-
NCT03098979 -
2016-004062-26
-
- Other papers using this trial's data
- Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03098979. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-10 (actual); primary completion 2018-05-23 (actual). Results posted on 2019-07-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
- Acronym
- PANACHE
- Condition
- Heart Failure
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct03098979- Content hash
9ed87c2a8f9138a1ca604af75ae2b5caff60d150bc102e349b134522a5722be4